BCRX Biocryst Pharmaceuticals Inc
Price (delayed)
$7.95
Market cap
$1.64B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.73
Enterprise value
$2.42B
BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of
Highlights
BCRX's EPS is up by 43% YoY and by 32% from the previous quarter
The net income has increased by 40% year-on-year and by 30% since the previous quarter
Biocryst Pharmaceuticals's quick ratio has decreased by 47% YoY and by 20% QoQ
BCRX's equity is down by 22% year-on-year
Key stats
What are the main financial stats of BCRX
Market
Valuations
Earnings
Shares outstanding
206.89M
Market cap
$1.64B
Enterprise value
$2.42B
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
4.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.32
Revenue
$382.24M
EBIT
-$45.33M
EBITDA
-$43.86M
Free cash flow
-$85.8M
Per share
Balance sheet
Liquidity
EPS
-$0.73
Free cash flow per share
-$0.42
Book value per share
-$2.3
Revenue per share
$1.85
TBVPS
$2.29
Total assets
$472.42M
Total liabilities
$948.03M
Debt
$850.64M
Equity
-$475.61M
Working capital
$234.39M
Debt to equity
-1.79
Current ratio
2.82
Quick ratio
2.65
Net debt/EBITDA
-17.57
Margins
Efficiency
Dividend
EBITDA margin
-11.5%
Gross margin
98.5%
Net margin
-38.2%
Operating margin
-15.8%
Return on assets
-29.5%
Return on equity
N/A
Return on invested capital
-4.1%
Return on capital employed
-13.2%
Return on sales
-11.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BCRX stock price
How has the Biocryst Pharmaceuticals stock price performed over time
Intraday
0.38%
1 week
2.85%
1 month
4.06%
1 year
5.58%
YTD
32.72%
QTD
28.64%
Financial performance
How have Biocryst Pharmaceuticals's revenue and profit performed over time
Revenue
$382.24M
Gross profit
$376.34M
Operating income
-$60.32M
Net income
-$145.93M
Gross margin
98.5%
Net margin
-38.2%
The operating margin has soared by 57% YoY and by 38% from the previous quarter
BCRX's net margin has soared by 52% YoY and by 35% QoQ
BCRX's operating income is up by 47% YoY and by 33% QoQ
The net income has increased by 40% year-on-year and by 30% since the previous quarter
Growth
What is Biocryst Pharmaceuticals's growth rate over time
Valuation
What is Biocryst Pharmaceuticals stock price valuation
P/E
N/A
P/B
N/A
P/S
4.29
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
6.32
BCRX's EPS is up by 43% YoY and by 32% from the previous quarter
BCRX's equity is down by 22% year-on-year
The P/S is 75% lower than the 5-year quarterly average of 16.8 but 22% higher than the last 4 quarters average of 3.5
BCRX's revenue is up by 25% YoY and by 8% QoQ
Efficiency
How efficient is Biocryst Pharmaceuticals business performance
BCRX's ROS has soared by 72% YoY and by 59% from the previous quarter
The ROIC has soared by 69% YoY and by 56% QoQ
The company's return on assets rose by 35% YoY and by 28% QoQ
Dividends
What is BCRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BCRX.
Financial health
How did Biocryst Pharmaceuticals financials performed over time
Biocryst Pharmaceuticals's total assets is 50% lower than its total liabilities
Biocryst Pharmaceuticals's current ratio has decreased by 48% YoY and by 24% from the previous quarter
Biocryst Pharmaceuticals's quick ratio has decreased by 47% YoY and by 20% QoQ
BCRX's equity is down by 22% year-on-year
BCRX's debt to equity is up by 16% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.